Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

AL Petzer, CJ Eaves, PM Lansdorp, L Ponchio, MJ Barnett, AC Eaves, Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia Blood. ,vol. 88, pp. 2162- 2171 ,(1996) , 10.1182/BLOOD.V88.6.2162.BLOODJOURNAL8862162

C Sirard, P Laneuville, JE Dick, Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism Blood. ,vol. 83, pp. 1575- 1585 ,(1994) , 10.1182/BLOOD.V83.6.1575.1575

L S Steelman, S C Pohnert, J G Shelton, R A Franklin, F E Bertrand, J A McCubrey, JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. ,vol. 18, pp. 189- 218 ,(2004) , 10.1038/SJ.LEU.2403241

Hagop M Kantarjian, Susan O'Brien, Jorge E Cortes, Sergio A Giralt, Mary Beth Rios, Jianqin Shan, Francis J Giles, Deborah A Thomas, Stefan Faderl, Marcos De Lima, Guillermo Garcia-Manero, Richard Champlin, Ralph Arlinghaus, Moshe Talpaz, None, Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia Blood. ,vol. 100, pp. 1590- 1595 ,(2002) , 10.1182/BLOOD.V100.5.1590.H81702001590_1590_1595

Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb, Anthony Rosenzweig, Robert N Salomon, Richard A Van Etten, Joseph Alroy, Jean-Bernard Durand, Thomas Force, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine. ,vol. 12, pp. 908- 916 ,(2006) , 10.1038/NM1446

Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, Moshe Talpaz, Brian Druker, None, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia The New England Journal of Medicine. ,vol. 346, pp. 645- 652 ,(2002) , 10.1056/NEJMOA011573

Ruibao Ren, Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer. ,vol. 5, pp. 172- 183 ,(2005) , 10.1038/NRC1567

Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561

Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes, Klaus Lechner, Johan L Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John Shepherd, Bengt Simonsson, Alois Gratwohl, John M Goldman, Hagop Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E Bolton, Renaud Capdeville, Brian J Druker, None, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia The New England Journal of Medicine. ,vol. 348, pp. 994- 1004 ,(2003) , 10.1056/NEJMOA022457

Jaap Verweij, Paolo G. Casali, Dusan Kotasek, Axel Le Cesne, Peter Reichard, Ian R. Judson, R. Issels, Allan T. van Oosterom, Martine Van Glabbeke, Jean-Yves Blay, Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005 European Journal of Cancer. ,vol. 43, pp. 974- 978 ,(2007) , 10.1016/J.EJCA.2007.01.018